DUBLIN--(BUSINESS WIRE)--Dublin - Research and Markets (http://www.researchandmarkets.com/research/13eda925/polycystic_kidney) has announced the addition of GlobalData's new report "Polycystic Kidney Disease (PKD) Therapeutics - Pipeline Assessment and Market Forecasts to 2019" to their offering.
GlobalData, the industry analysis specialist, has released its new report, Polycystic Kidney Disease (PKD) Therapeutics - Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information and analysis on the global Polycystic kidney disease Therapeutics market. The report identifies the key trends shaping and driving the global Polycystic kidney disease Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Polycystic kidney disease Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
The Pkd Therapeutics Market is Forecast to Grow until 2019
The global PKD therapeutics market was worth $111.4m in 2006, and grew at a Compound Annual Growth Rate (CAGR) of 1.7% to reach $121.0m in 2011. The market is forecast to grow at a CAGR of 16.1% over the next eight years to reach $400.2m by 2019. This growth is primarily attributed to the expected launch of Samsca (tolvaptan) for the treatment of patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). The scheduled patent expiries of Cozaar (US and Europe), Aceon (US), Coreg (US) and Diovan (Europe) are expected to have a minimal impact on the PKD therapeutics market as the annual cost of therapy associated with these drugs is significantly low.
Key Topics Covered:
1 List of Tables and Figures
2 Polycystic Kidney Disease (PKD) Therapeutics - Introduction
3 Polycystic Kidney Disease Therapeutics - Market Characterization
4 Polycystic Kidney Disease Therapeutics - Competitive Assessment
5 Polycystic Kidney Disease Therapeutics - Pipeline Assessment
6 Polycystic Kidney Disease Therapeutics - Clinical Trials Mapping
7 Polycystic Kidney Disease Therapeutics - Strategic Assessment
8 Polycystic Kidney Disease Therapeutics - Future Players
9 Polycystic Kidney Disease Therapeutics - Licensing and Partnership Deals
10 Polycystic Kidney Disease Therapeutics - Appendix
Companies Mentioned:
- Novartis AG
- Otsuka Holdings Co., Ltd.
For more information visit http://www.researchandmarkets.com/research/13eda925/polycystic_kidney
Source: GlobalData